← Leaderboards
David G Brooks
Boston Immune Technologies And Therapeutics, Inc.
$3,974,764
Attributed
$3,974,764
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.4M · FY2024–25$2.5M$1.9M$1.3M$625K$0
'24
'25
Funding mix
By agency
NIH$3,974,764 · 1
By mechanism
R44$3,974,764 · 1
Top collaborators
No co-investigators on record.
Most similar at Boston Immune Technologies And Therapeutics, Inc.
Same institution · by research overlap
- Kenneth Olivier$3,621,523
Others in their field
Other Rising Stars on “Acceleration”
- Angee Greer · Ppd Development Lp$82,531,927
- Julia Louise Moore Vogel · Scripps Research Institute, The$32,252,685
- Tim A Bertram · Wake Forest University School Of Medicine$30,163,580
- Nancy Jean Sullivan · Boston University Medical Campus$23,000,000
- Alanna Maguire · Mayo Clinic Rochester$16,353,346
- Michael Hogarth · University Of California, San Diego$15,375,743
Research focus
AccelerationAnimal ModelAntagonistAdvocacy OrganizationsAntitumor EffectAwardBiological MarkersBiomarker EvaluationAntibodiesBlood SpecimenBostonBurden Of IllnessCancer CellCancer PatientCancer TherapyCellsCgmp ProductionClinical ApplicationClinical TrialsBirdsCollaborationsCutaneous T-Cell LymphomaCyclic GmpDesign
Grant awards (2)
Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).$2,409,283
R44 · FY2025 · CA · contact PI
Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).$1,565,481
R44 · FY2024 · CA · contact PI